Physician profile
William Chu
NPI 1043227804
$13,252.13
in general payments reported to CMS, 2019-2025
27 companies · $2,352 in 2025
The $2,352 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,439 · 2022: $3,062 · 2023: $3,561 · 2024: $2,839 · 2025: $2,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,751.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,681.59 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $2,392.07 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Horizon Therapeutics Plc | $1,951.18 | 2021-2023 | Krystexxa |
| Abbvie INC. | $873.71 | 2022-2025 | |
| Novo Nordisk INC | $591.71 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $576.03 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $493.19 | 2022-2025 | |
| Lilly USA, LLC | $428.09 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Ardelyx, INC. | $422.95 | 2024-2025 | Ibsrela |
| Verona Pharma, INC. | $417.40 | 2025 | Ohtuvayre |
| Ironwood Pharmaceuticals, INC | $291.04 | 2022-2024 | Linzess |
| Amarin Pharma, INC. | $237.66 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.22 | 2022-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $224.95 | 2022-2023 | Vemlidy |
| Dexcom, INC. | $204.23 | 2024-2025 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $176.29 | 2022-2023 | Nexletol |
| Abbott Laboratories | $175.89 | 2024-2025 | Gallant, Aveir, Assurity |
| Phathom Pharmaceuticals, INC. | $172.56 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.91 | 2022-2024 | Jardiance |
| Redhill Biopharma INC. | $135.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
| Pfizer INC. | $117.77 | 2021-2025 | |
| Exact Sciences Corporation | $70.42 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $51.89 | 2022-2023 | |
| Janssen Biotech, INC. | $20.84 | 2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $19.46 | 2021 | |
| Merck Sharp & Dohme LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.